Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].
Molecular Weight:
306.37
Purity:
99.99
CAS Number:
[941678-49-5]
Formula:
C17H18N6
Target:
Apoptosis,Autophagy,JAK,Mitophagy
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
